🇺🇸 FDA
Patent

US 12060396

Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis

granted A61KA61K38/00A61K38/1709

Quick answer

US patent 12060396 (Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis) held by THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Grant date
Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K38/00, A61K38/1709, A61K38/1777, A61K38/1825